(P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)?

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This study suggests that certain patients with high-risk prostate cancer may be effectively treated with a shorter course of hormone ablation therapy. Longer follow-up and more patients will be needed to verify the efficacy of a shorter course of hormone ablation therapy in this patient population.

Seungtaek Choi, MD, Quynh-Nhu Nguyen, MD, Sean E. McGuire, MD, PhD, Karen E. Hoffman, MD, MPH, Thomas J. Pugh, MD, Steven J. Frank, MD, Usama Mahmood, MD, Deborah A. Kuban, MD, Andrew K. Lee, MD, MPH; UT MD Anderson Cancer Center

PURPOSE: To determine the efficacy of a shorter course of androgen deprivation therapy (ADT) in patients with high-risk prostate cancer.

MATERIALS AND METHODS: Charts of 472 high-risk prostate cancer (stage ≥ T3a, Gleason ≥ 8, or prostate-specific antigen [PSA] > 20.0 ng/mL) treated between 2000 and 2012 were reviewed. Eighty patients who were treated with a shorter course of ADT (≤ 12 mo of a gonadotropin-releasing hormone [GnRH] agonist) were analyzed for this study. All patients were treated with image-guided radiation therapy with either intensity-modulated radiation therapy or proton therapy. The median total dose given was 76 Gy in 2-Gy fractions (range: 74–86.4 Gy in 1.8–2.0-Gy fractions). Patients were followed with PSA measurements taken at 3–6-month intervals after the radiation therapy. Biochemical failure was defined as nadir + 2 as per the Phoenix definition. Biochemical relapse–free survival and prostate cancer–specific survival were calculated using the Kaplan-Meier method.

RESULTS: Median age was 73 years (range: 52–89 yr). The ADT duration was ≤ 6 months in 18 patients (22.5%) and 9–12 months in 62 patients (77.5%). The distribution of T stage was as follows: 1 patient with TX (1.3%), 31 with T1c (38.8%), 23 with T2a (27.5%), 10 with T2b (12.5%), 5 with T2c (6.2%), 6 with T3a (7.5%), and 5 with T3b (6.2%). The distribution of Gleason scores was as follows: 6 patients (7.5%) with Gleason 7 (3 + 4), 9 (11.2%) with Gleason 7 (4 + 3), 53 (66.2%) with Gleason 8 (4 + 4), 11 (13.8%) with Gleason 9 (4 + 5), and 1 (1.3%) with Gleason 9 (5 + 4). Four patients had PSA < 4 ng/mL (5.0%), 48 patients had PSA 4.1–10 ng/mL (60.0%), 19 patients had PSA 10.1–20 ng/mL (23.8%), and 9 patients had PSA > 20 ng/mL (11.2%). The majority of patients had disease at the lower end of the high-risk spectrum (stage ≤ T2 [85.0%], Gleason ≤ 8 [84.9%], and PSA ≤ 20 ng/mL [88.8%]). Median follow-up was 38 months (range: 3–158 mo). Actuarial 4-year biochemical relapse–free survival was 91%. There were four biochemical failures seen, with a median time to failure of 33.5 months (range: 27–48 mo). There was no significant correlation between T stage, Gleason score, PSA, or duration of hormone ablation therapy and recurrence. Although there were 10 deaths in this patient population, none of the deaths was related to prostate cancer.

CONCLUSIONS: This study suggests that certain patients with high-risk prostate cancer may be effectively treated with a shorter course of hormone ablation therapy. Longer follow-up and more patients will be needed to verify the efficacy of a shorter course of hormone ablation therapy in this patient population.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content